Skip to main content

Branched Peptides

Branched Peptide Knowledge Center

A branched peptide is one in which a second chain, or a non-peptide group, is attached through an amino acid side chain rather than through the backbone. That single structural change is behind several unrelated things: multiple antigenic peptides that raise antibodies without a carrier protein, acylated drug candidates that last a week in circulation, and bi-epitopic constructs that carry two sequences on one molecule. The branch point is almost always a lysine side-chain amine.

Four branched peptide architectures: a linear peptide for comparison; a side-chain conjugate where one lysine carries a fatty acid, PEG or label, the architecture of acylated drug candidates including semaglutide; a branched peptide carrying two different sequences on one lysine core; and a MAP or dendrimer presenting four or eight copies of one sequence on a lysine core.
The architectures differ in what is attached and how many copies, but all of them open at the same place: a lysine side-chain amine.

Start here

What counts as a branched peptide

The term covers more ground than it first appears to, and the four cases below are built the same way but sold for different reasons.

ArchitectureWhat is attachedWhy it is used
Side-chain conjugateA fatty acid, PEG chain, dye, biotin or drug payload on one lysineHalf-life extension, labeling, targeted delivery. The structure of the acylated GLP-1 analogues.
Bi-epitopic branchTwo different peptide sequences on one lysine corePresenting two epitopes together, or a targeting sequence plus a payload
MAP and dendrimersFour or eight copies of one sequence on a branched lysine coreRaising antibodies without conjugating to a carrier protein1
Branched cyclicA side chain joined back to the backbone or to another side chainConformational constraint and protease resistance

Why a branch changes behaviour

Three effects account for most of the uses, and they are worth separating because a design usually exploits one of them rather than all three.

  • Avidity. Several copies of a binding sequence on one molecule can engage several sites at once. Rebinding makes the complex dissociate more slowly, so the functional affinity is higher than the single-site affinity measured for the monomer. This is the basis of the MAP immunogen and of multivalent binding reagents.
  • Protease resistance. A branch point is not a normal backbone amide, and the residues around it are sterically crowded, so exopeptidases that chew inward from a terminus are slowed.
  • An attachment site that is not a terminus. Sometimes the point is simply that both termini have to stay free, or that the appended group must sit at a defined internal position. A lysine side chain gives a third place to attach something.

The branch is not free. Every branch point roughly doubles the number of couplings that have to succeed, and a failure on one arm gives a product that differs from the target by a whole sequence rather than by one residue. Branched peptides are therefore harder to purify and harder to characterise than linear ones of the same total length, and the analysis matters as much as the synthesis.

Related services and reading

References

  1. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proceedings of the National Academy of Sciences USA 1988;85(15):5409–5413. doi:10.1073/pnas.85.15.5409